PSEN1 and Alzheimer disease: When GSK-3β phosphorylates PS1 at the Ser353/357 residues, the phosphorylated PS1 reduces its binding to N-cadherin and β-catenin, impairing survival signaling in neurons and thereby contributing to AD [160].